[1] Sifuentes-Osornio J,Corzo-León DE,Ponce-de-León LA.Epidemiology of invasive fungal infections in Latin America [J].Curr Fungal Infect Rep,2012,6(1):23-34.
[2] Chaffin WL.Candida albicans cell wall proteins [J].Microbiol Mol Biol Rev,2008,72(3):495-544.
[3] Hata K,Horii T,Miyazaki M,et al.Efficacy of oral E1210,a new broad-spectrum antifungal with a novel mechanism of action,in murine models of candidiasis,aspergillosis,and fusariosis [J].Antimicrob Agents Chemother,2011,55(10):4543-4551.
[4] Miyazaki M,Horii T,Hata K,et al.In vitro antifungal activity of E1210,a novel antifungal,against clinically important yeasts and molds [J].Antimicrob Agents Chemother,2011,55(10):4652-4658.
[5] Pfaller MA,Duncanson F,Messer SA,et al.In vitro activity of a novel broad-spectrum antifungal,E1210,tested against Aspergillus spp.determined by CLSI and EUCAST broth microdilution methods [J].Antimicrob Agents Chemother,2011,55(11):5155-5158.
[6] Pfaller MA,Watanabe N,Castanheira M,et al.Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida:comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods [J].J Antimicrob Chemother,2011,66(11):2581-2584.
[7] Pfaller MA,Hata K,Jones RN,et al.In vitro activity of a novel broad-spectrum antifungal,E1210,tested against Candida spp.as determined by CLSI broth microdilution method [J].Diagn Microbiol Infec Dis,2011,71(2):167-170.
[8] Castanheira M,Duncanson FP,Diekema DJ,et al.Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against FusariumandScedosporium species identified using molecular methods [J].Antimicrob Agents Chemother,2012,56(1):352-357.
[9] Watanabe NA,Miyazaki M,Horii T,et al.E1210,a new broad-spectrum antifungal,suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis [J].Antimicrob Agents Chemother,2012,56(2):960-971.
[10] Wiederhold NP,Najvar LK,Fothergill AW,et al.The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans [J].Antimicrob Agents Chemother,2015,59(1):690-692.
[11] Kitamura A,Someya K,Okumura R,et al.In vitro antifungal activities of D11-2040,a β-1,6-glucan inhibitor,with or without currently available antifungal drugs [J].Biol Pharm Bull,2010,33(2):192-197.
[12] Kitamura A,Someya K,Hata M,et al.Discovery of a small-molecule inhibitor of β-1,6-glucan synthesis [J].Antimicrob Agents Chemother,2009,53(2):670-677.
[13] Baxter BK,DiDone L,Ogu D,et al.Identification,in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules [J].ACS Chem Biol,2011,6(5):502-510.
[14] Roelants FM,Torrance PD,Thorner J.Differential roles of PDK1-and PDK2-phosphorylation sites in the yeast AGC kinases Ypk1,Pkc1 and Sch9 [J].Microbiology,2004,150(10):3289-3304.
[15] Zeng Z,Samudio IJ,Zhang W,et al.Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia [J].Cancer Res,2006,66(7):3737-3746.
[16] Cowen LE,Singh SD,Khler JR,et al.Harnessing Hsp90 function as a powerful,broadly effective therapeutic strategy for fungal infectious disease [J].Proc Natl Acad Sci U S A,2009,106(8):2818-2823.
[17] Cowen LE.The evolution of fungal drug resistance:modulating the trajectory from genotype to phenotype [J].Nat RevMicrobiol,2008,6(3):187-198.
[18] Blum G,Kainzner B,Grif K,et al.In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus [J].Clin Microbiol Infect,2013,19(1):50-55.
[19] Kamal A,Thao L,Sensintaffar J,et al.A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors [J].Nature,2003,425(6956):407-410.
[20] Gao J,Xiao S,Liu X,et al.Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro [J].Virol J,2014,11(1):17.
[21] Pachl J,Svoboda P,Jacobs F,et al.A randomized,blinded,multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis [J].Clin Infect Dis,2006,42(10):1404-1413.
[22] Louie A,Stein DS,Zack JZ,et al.Dose range evaluation ofMycograb C28Y variant,a human recombinant antibody fragment to heat shock protein 90,in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis [J].Antimicrob Agents Chemother,2011,55(7):3295-3304.
[23] Matthews RC,Rigg G,Hodgetts S,et al.Preclinical assessment of the efficacy of mycograb,a human recombinant antibody against fungal HSP90 [J].Antimicrob Agents Chemother,2003,47(7):2208-2216.
[24] Moragues MD,Omaetxebarria MJ,Elguezabal N,et al.A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C.albicans activities [J].Infect Immun,2003,71(9):5273-5279.
[25] Sevilla MJ,Robledo B,Rementeria A,et al.A fungicidal monoclonal antibody protects against murine invasive candidiasis [J].Infect Immun,2006,74(5):3042-3045.
[26] Brena S,Omaetxebarría MJ,Elguezabal N,et al.Fungicidal monoclonal antibody C7 binds to Candida albicans Als3 [J].Infect Immun,2007,75(7):3680-3682.
[27] Brena S,Cabezas-Olcoz J,Moragues MD,et al.Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans [J].Antimicrob Agents Chemother,2011,55(7):3156-3163.
[28] Dadachova E,Nakouzi A,Bryan RA,et al.Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection [J].Proc Natl Acad Sci U S A,2003,100(19):10942-10947.
[29] Bryan RA,Jiang Z,Howell RC,et al.Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection [J].J Infect Dis,2010,202(4):633-637.
[30] Jiang Z,Bryan RA,Morgenstern A,et al.Treatment of early and establishedCryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice [J].Antimicrob Agents Chemother,2012,56(1):552-554.
[31] Larsen RA,Pappas PG,Perfect J,et al.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis [J].Antimicrob Agents Chemother,2005,49(3):952-958.
[32] DeBernardis F,Amacker M,Arancia S,et al.A virosomal vaccine against candidal vaginitis:immunogenicity,efficacy and safety profile in animal models [J].Vaccine,2012,30(30):4490-4498.
[33] Xin H,Cartmell J,Bailey JJ,et al.Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis [J].PloS One,2012,7(4):e35106.
[34] Quan H,Cao YY,Xu Z,et al.Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole [J].Antimicrob Agents Chemother,2006,50(3):1096-1099.
[35] 权华.小檗碱与氟康唑协同抗耐药白念珠菌的作用及作用机制研究 [D].上海:第二军医大学,2006.
[36] Xu Y,Wang Y,Yan L,et al.Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation [J].J Proteome Res,2009,8(11):5296-5304.
[37] 许懿.小檗碱与氟康唑协同抗耐药白念珠菌的作用机制研究 [D].上海:第二军医大学,2010.
[38] Gallo-Ebert C,Donigan M,Stroke IL,et al.Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor [J].Antimicrob Agents Chemother,2014,58(1):258-266.
[39] Hata M,Ishii Y,Watanabe E,et al.Inhibition of ergosterol synthesis by novel antifungal compounds targeting C-14 reductase [J].Med Mycol,2010,48(4):613-621.
[40] Xu D,Ondeyka J,Harris GH,et al.Isolation,structure,and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (chaetothyriales) using the genome-wide Candida albicans fitness test [J].J Nat Prod,2011,74(8):1721-1730.
[41] Rock FL,Mao W,Yaremchuk A,et al.An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site [J].Science,2007,316(5832):1759-1761.
|